Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.

MLA

Bowring, Mary G., et al. “Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.” Transplantation, vol. 102, no. 12, Dec. 2018, pp. 2088–95. EBSCOhost, https://doi.org/10.1097/TP.0000000000002323.

APA

Bowring, M. G., Kucirka, L. M., Massie, A. B., Ishaque, T., Bae, S., Shaffer, A. A., Garonzik Wang, J., Sulkowski, M., Desai, N., Segev, D. L., & Durand, C. M. (2018). Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. Transplantation, 102(12), 2088–2095. https://doi.org/10.1097/TP.0000000000002323

Chicago

Bowring, Mary G, Lauren M Kucirka, Allan B Massie, Tanveen Ishaque, Sunjae Bae, Ashton A Shaffer, Jacqueline Garonzik Wang, et al. 2018. “Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.” Transplantation 102 (12): 2088–95. doi:10.1097/TP.0000000000002323.